Connection

Andrew Kraft to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Andrew Kraft has written about Antineoplastic Agents.
Andrew Kraft
Connection Strength
2.148
Antineoplastic Agents
  1. Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget. 2017 May 02; 8(18):30199-30216.
    View in: PubMed
    Score: 0.338
  2. PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther. 2015 Jul; 151:41-9.
    View in: PubMed
    Score: 0.291
  3. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008 Sep 05; 283(36):25003-13.
    View in: PubMed
    Score: 0.183
  4. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol Cancer Ther. 2008 May; 7(5):1091-100.
    View in: PubMed
    Score: 0.181
  5. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005 Mar; 4(3):443-9.
    View in: PubMed
    Score: 0.145
  6. Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study. Melanoma Res. 1999 Dec; 9(6):599-606.
    View in: PubMed
    Score: 0.101
  7. Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Prostate. 1998 Feb 15; 34(3):175-81.
    View in: PubMed
    Score: 0.089
  8. Biological activity of 26-succinylbryostatin 1. Biochim Biophys Acta. 1996 Jul 24; 1312(3):197-206.
    View in: PubMed
    Score: 0.080
  9. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res. 1996 Feb 15; 56(4):802-8.
    View in: PubMed
    Score: 0.078
  10. Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res. 1995 Sep 01; 55(17):3716-20.
    View in: PubMed
    Score: 0.075
  11. A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
    View in: PubMed
    Score: 0.065
  12. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res. 1993 Jun 15; 53(12):2810-5.
    View in: PubMed
    Score: 0.065
  13. Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia. 1991 Apr; 5(4):283-7.
    View in: PubMed
    Score: 0.055
  14. Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res. 1990 Sep 01; 50(17):5520-5.
    View in: PubMed
    Score: 0.053
  15. Role of thoracic radiotherapy combined with chemotherapy in limited stage small cell lung cancer (SCLC). A randomized multicenter phase III trial. Onkologie. 1990 Aug; 13(4):253-8.
    View in: PubMed
    Score: 0.053
  16. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3133-40.
    View in: PubMed
    Score: 0.049
  17. Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. 1989 Mar 01; 49(5):1287-93.
    View in: PubMed
    Score: 0.048
  18. Regulation of RUNX1/AML1 during the G2/M transition. Leuk Res. 2007 Jun; 31(6):839-51.
    View in: PubMed
    Score: 0.041
  19. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005 Apr 01; 103(7):1431-8.
    View in: PubMed
    Score: 0.037
  20. Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000 Nov; 6(11):4205-8.
    View in: PubMed
    Score: 0.027
  21. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res. 1999 Sep; 5(9):2344-8.
    View in: PubMed
    Score: 0.025
  22. Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res. 2015 Dec 15; 75(24):5318-28.
    View in: PubMed
    Score: 0.019
  23. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Oncotarget. 2014 Sep 30; 5(18):8503-14.
    View in: PubMed
    Score: 0.018
  24. Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86.
    View in: PubMed
    Score: 0.012
  25. Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci U S A. 1987 Dec; 84(23):8483-7.
    View in: PubMed
    Score: 0.011
  26. [Therapy of small-cell bronchial carcinoma]. Dtsch Med Wochenschr. 1984 Jun 08; 109(23):913-5.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.